StocksMedium•5 November 2026•
1 min read
Entrada Therapeutics Reports $0.94 Q3 Loss Per Share
Key Facts
1Entrada Therapeutics reported a quarterly loss of $0.94 per share, narrower than the Zacks Consensus Estimate of a loss of $0.98.
2The current quarter's results compare to a loss of $1.06 per share in the same period a year ago.
Entrada Therapeutics reported a quarterly loss of $0.94 per share for the third quarter of 2026. Zacks reported that this figure was narrower than the analyst consensus estimate of a $0.98 loss per share, and shows an improvement from the $1.06 loss per share recorded in the same period last year.
TRDA closed at $5.06 on November 4, 2026, with the stock trading between a low of $4.61 and a high of $5.13 during that session. These financial results were released as part of the company's standard reporting cycle, reflecting a mixed performance profile between the earnings per share beat and the third-quarter revenue figures.